Tom,
Thanks for your input. I believe ABS2000 approval is nearly a given at this point. And judging from what we have NOT heard from the FDA, the approval will probably be unconditional. Usually if there is some kind of problem, something the FDA doesn't like, this would be communicated to the company for correction or discussion. I know of no such objections from the FDA for the ABS.
As far as status reports go: every 30 days is for an official update. I believe a company has much more dialogue with FDA at this stage of the approval process e.g. conference calls, informal communication via phone and fax, etc.
I agree that Blud has a plan to develop the company into a major international player in the blood analysis field. But, BLUD also has a shareholders "rights plan" which says that any buy out offer must be considered by the board and, if approved, brought to the shareholders for approval. The board is not totally comprised of directors from management e.g. Kenneth Dart , who has approx. 500,000 shares has a representative on the board. If a buyout offer is good enough , which way do you think he will vote ? With the right offer, especially if present management is retained after the buy out, BLUD will cease to exist....at least as a sole entity.
If a take over doesn't happen then a partner distribution agreement with a major company is imperative IMO. the ABS is bigger than BLUD, and the company doesn't have enough time to grow into it.
Sorry for the long post. Lastly, I don't really see the connection between the IBG deal and ABS approval.
BTW: the two biggest trades today...3500 shares and 2000 shares ...were both buys...at 9 15/16... low vol. of 13000 shares
|
